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S _inary Ewing tumours (ET), including Ewing's sarcoma and peripheral primitive neuroectodermal
tumour, are well characterised at the molecular level by a unique chromosomal rearrangement which fuses the
EWS gene to one of two closely related ETS proto-oncogenes, FLI-1 or ERG. Expression of the resulting
chimaeric transcripts can be readily detected by reversed transcriptase polymerase chain reaction (RT-PCR).
This approach led to the identification of a number of different exon combinations at the junction site of
coding sequences. The physiological consequences of the observed variability in the hinge region of EWS
chimaeric proteins are not known. We have analysed tumour-derived material from 30 ET patients with
well-documented clinical course (18 with localised and 12 with metastatic disease at diagnosis) for the presence
of EWSI'FLI-1 or EWS/ERG RNA. Karyotypes were obtained in 21 out of 27 cases and analysed by routine
cytogenetics. A chromosome 22 rearrangement was demonstrated in 18 cases (67%). In contrast, RT-PCR
revealed the presence of chimaeric transcripts in 28 tumours (93%), with fusions of EWS exon 7 to FLI-1
exons 6 (19/28), 5 (4/28) and 7 (1/28). In addition, EWSIFLI-I exon combinations 10/5 and 9/4 were observed
in one case each. In the last tumour, the presence of at least four additional splicing variants corresponding to
fusion of EWS exon 7 to FLI-1 exons 4, 6, 8 and 9 was demonstrated. Two tumours expressed EWSIERG
fusion transcripts involving EWS exon 7 and ERG exon 6. In this study, EWSIFLI-1 exon combinations 7/6
(type I) predominated over 7/5 (type II) in localised ET (14 versus 1) and were more abundant in tumours
affecting the long bones (9 versus 0), whereas in central axis tumours and metastatic disease there was only
little difference in the frequency of the two types. So far, no correlations between different chimaeric EWS
transcnpts and any other clinical parameters have been identified.
Among cytogenetic aberrations in Ewing's sarcoma (ES) and
peripheral primitive neuroectodermal tumours (pPNET),
recently referred to as 'Ewing tumours' (ET), the reciprocal
translocation between the long arms of chromosomes 11 and
22, t(I1;22)(q24;q12) occurs in 83% of cases. In an additional
9% complex translocations involving chromosome 22 have
been identified (Aurias et al., 1983; Turc-Carel et al., 1983;
Whang-Peng et al., 1984). Moreover, tumour cells of ES and
pPNET are well characterised by the extraordinary high
expression of the pseudoautosomal MIC2P3-32 gene (Kovar
et al., 1990), which represents a highly selective feature of
these cells, making an assignment of these small round-cell
tumours as one entity even more likely (Ambros et al.,
1991).
The recent cloning of the chromosome breakpoints of the
ET-specific t(I 1;22) translocation revealed that the sites of
rearrangement were localised within two regions, EWSR1
and EWSR2, on chromosome 22 and 11 respectively (Zuc-
man et al., 1992). On chromosome 22, EWSR1 is nested
within a novel gene of unknown function, EWS (Plougastel
et al., 1993). The gene involved in the translocation on
chromosome 11 was revealed to encode the human homo-
logue of murine FLI-l, a member of the ETS family of
transcription factors. In mice, FLI-1 resides at the insertion
site of Friend murine leukaemia virus in induced erythro-
leukaemias. Proviral integration causes FLI-1 activation and
consequently neoplastic transformation of erythroid pro-
genitor cells. As a result of the gene rearrangement in human
ET cells, the C-terminal FLI-1 portion is constitutively ex-
pressed from the EWS gene promoter as part of a chimaeric
protein. In addition to FLI-I rearrangements, fusion of EWS
to the closely related ETS proto-oncogene ERG, located on
chromosome 21q22, was revealed in t(ll;22)(q24;qI2)-nega-
tive ETs (Zucman et al., 1993; Sorenson et al., 1994). The
positions of the chromosome translocation breakpoints were
shown to be restricted to introns 7-10 of the EWS gene and
widely dispersed within introns 3-9 of the ETS-related genes.
Among the rearrangements that result in in-frame exon fusion,
joining of exon 7 of EWS to either exon 6 or 5 of FLI-I has
been observed most frequently (81%) (Zucman et al., 1993).
These rearrangements correspond to type I and II fusion
transcripts originally reported by Delattre et al. (1992). Re-
garding the EWS/ERG rearrangements, four different
chimaeic transcripts have been reported so far (Zucman et al.,
1993). The minimal coding sequences present in all El-specific
fusion transcripts is composed of EWS exons 1-7 and by the
FLI-I or ERG region downstream of the exon 8/9 boundary.
These RNAs encode chimaenc proteins with a C-terminal
glutamine-nrch EWS regulatory domain (EWS-RD) fused via a
variable hinge region to a unique DNA-binding domain that is
charcteristic of all ETS transcription factors. The activity of a
second transactivating domain, which resides in the C-terminus
of FLI-I or ERG, is dependent on the presence of EWS-RD
(Ohno et al., 1993). However, nothing is known about the
function and the physiological consequences of the variant
region lying in between EWS-RD and the DNA-binding
domain, except that type I and a chimaeric transcript 66 bp
shorter than type I transform NIH-3T3 cells equally well
(May et al., 1993). We now report on the analysis ofdifferent
gene fusions and accessory splicing variants in 30 ETs by
means of RT-PCR. The molecular data are compared with
all relevant clinical data available in order to identify any
correlations of specific EWS chimaeric variants with the
course of the disease in ET patients.
Materials and methods
Patients and tumours
The tumour-derived material analysed in this study
originated from 30 ET patients. 14 females and 16 males with
a median age of 13 years (range 3-25) (Table I). Eight
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Table I Patients characteristics and clinical data
Patient Age (years) Metastases Chromosome 22
no. sex Localisation at diagnosis RNA rearrangement
I 13F Humerus None EWS ex 71FLI-i ex 6 t(l1;22)
2 16M Fibula None EWS ecx 9/FLI-i ex 4 del 22q
3 lOF Femur None EWS ecx 7/FLI-i ex 6 t(ll;22)
4 3F Chest wall None EWS ex 7/FLI-i ex 6 t(ll;22)
5 14M Femur Bone marrow Negative neg
6 9M Fibula Bone marrow EWS ex 7/FLI-i ex 6 t(ll;22)
7 4F Chest wall None EWS ex 71FLI-i ex 5 t(ll;22)
8 16M Pelvis Lungs, bone EWS ex 7/FLI-i ex 5 t(ll;22)
9 16M Pelvis Lungs EWS ex 71FLI-i ex 6 t(ll;22)
10 lOF Chest wall Liver, lungs Negative t(2;22)
11 13M Scapula None EWS ex 71FLI-i ex 6 t(l1;22)
12 16F Chest wall Bone EWS ex 10/UFL-1 ex 5 t(6,11,22)
13 17M Multifocal Bone, bone marrow EWS ex 7/FLI-i ex 6 t(l1;22)
14 lOF Chest wall Bone EWS ex 7/FLI-i ex 5 t(l1;22)
15 12F Fibula None EWS ex 7/FLI-i ex 6 ND
16 17F Mandibula Lungs, bone EWS ex 71FLI-i ex 6 ND
17 16F Metatarsus None EWS ex 7/FLI-i ex 6 ND
18 4M Chest wall None EWS ex 7/FLI-i ex 6 ND
19 25M Pelvis Lungs, bone, bone marrow EWS ex 7/FLI-I ex 5 ND
20 6M Thumb None EWS ex 7/FLI-i ex 6 ND
21 15M Humerus Lungs, bone EWS ex 7/ERG ex 6 t(2;22)
22 IIF Chest wal} None EWS ex 7/ERG ex 6 Negative
23 7F Musc.iliopsoasa None EWS ex 7/FLI-i ex 7 t(11;22)
24 lIM Fibula None EWS ex 7/FLI-i ex 6 t(l1;22)
25 14M Pelvis None EWS ex 7/FLI-i ex 6 ND
26 8F Spine None EWS ex 7/FLI-i ex 6 ND
27 15M Tibia None EWS ex 7/FLI-i ex 6 ND
28 20F Pelvis Lun EWS ex 7/FLI-i ex 6 t(11;22)
29 3M Chest wall None EWS ex 7/FLI-i ex 6 t(11;22)
30 14M Chest wall None EWS ex 7/FLI-i ex 6 t(11;22)
'Extraosseous Ewing tumour. F, female; M, male; ND, not determined because of non-growth or insufficient amount of
material.
pnmary tumours were located in the lower extremities, eight
in the thoracopulmonary region, five in the pelvis, four in the
upper extremities, one in the manible and one in the spine;
one patient had multifocal bone disease. Two patiewnts had
tumours not involving the bone (extraosseous ET) evolving
from the iliopsoas muscle and the chest wall (patients 22 and
23 respectively). Moreover, two patients suffered from ETs as
second malignancies after acute lymphoblastic leukaemia and
large-cell anaplastic lymphoma (patients 23 and 28). At diag-
nosis, 18 patients presented with localised disease, whereas in
12 patients metastatic disease was revealed. Metastases to the
lungs could be found in seven patients, to the bones in seven
patients, to the bone marrow investigated by light micro-
scopy in four patients and to the liver in one patient.
Twenty-nine patients were treated according to the Co-
operative Ewing's Sarcoma Study (CESS) protocols (Jurgens
et al., 1988). One patient received the CWS 86 protocol for
soft-tissue sarcoma because of an extraosseous ET (Kosciel-
niak et al., 1991). Six patients with metastases at diagnosis
and two patients after relapse received autologous or
allogeneic bone marrow transplantation with a conditioning
regimen consisting of melphalan, etoposide and carboplatin
(Fmminger et al., 1991). Follow-up information was available
for 28 patients.
Collection of tumour samples
At least two surgical samples of tumour were collected from
every patient at diagnosis. After cryostat examination one
piece was formalin fixed and paraffin embedded for immun-
histochemical studies. The second part of the tumour was
dissected and placed into RPMI-1640 (Gibco, Paisley, UK)
for the derivation of cell lines and routine cytogenetic
analysis. Another part was immediately snap frozen in liquid
nitrogen and transferred to the laboratory on dry ice for
RNA preparation.
As negative controls for the RT-PCR analysis, RNA from
different solid tumours with a diagnosis other than ET were
used. They included three rhabdomyosarcomas, one lym-
phoma, one neuroblastoma, one osteosarcoma and one
malignant melanoma.
Immunohistochemistry
For diagnosis of small round cell tumours a panel of
antibodies was used directed towards MIC-2P"32 antigen
(12E7, R. Levy, Stanford University, USA; HBA71, G.
Hamilton, University of Vienna, Austria), vimentin, desmin
(Biomarker, Rehovot, Israel; D-1033, Sigma), common
leucocyte antigen, anti-muscle-specific actin (HHF-35, Enzo,
New York, NY, USA), HNK-I/Leu 7 (Becton Dickinson,
Sunnyvale, CA, USA), neuron-specific-enolase (Bioscience,
Emmenbriicke, Switzerland) and S-100 protein (Dakopatts,
Glostrup, Denmark). All tumours were reviewed by the
Vienna Bone Tumour Registry (M. Salzer-Kuntschik) and
classified as ETs according to the CESS criteria (Juirgens et
al., 1988; Ambros et al., 1991).
Nucleic acid isolation
Total RNAs from frozen tumours or cell lines were isolated
using the TRIzol extraction kit (Gibco BRL, Life Techno-
logies, Gaithersburg, MD, USA) based on the acid
guanidinium-phenol-chloroform method (Chomczynsli &
Sacchi, 1987).
Reverse transcription and PCR amplification
Aliquots of 1-4 iLg of total RNA were reversed transcribed
with either random hexamers, oligo-dT or with the FLI-I
specific primer 1 A (Table II) using Moloney munne leu-
kaemia virus reverse transcriptase (Gibco BRL, Life Techno-
logies).
The resulting cDNAs were PCR amplified using primers
11.3 and 22.3 (Delattre et al., 1992) or primers 22.3 and ERG
3 (Table II). Internal control for specific amplification was
provided by nested PCR using primers 11.4 and 22.4 or
primers 22.4 and ERG 4. In order to evaluate the quality of910 A. ZOUBEK et al.
Table k Primers used for RT-PCR experiments
Namne Geneiexon no. Sequence
11.3 Antisense FLI-I ex 9 ACTCCCCGTTGGTCCCCTCC
11.4 Antisense FLI-I ex 9 CAGGTGATGCAGCTGGCG
I .A Antisense FLI-I ex 9 AGAAGGGTACTTGTACATGG
22.3 Sense EWS ex 7 TCCTACAGCCAAGCTCCAGGTC
22.4 Sense EWS ex 7 CCAACAGAGCAGCAGCTAC
ERG 3 Antisense ERG ex 9 ACTCCCCGTTGGTGCCTTCC
ERG 4 Antisense ERG ex 9 CAGGTGATGCAGCTGGAG
MIC2 I Sense MIC2 ex 5 CCGATGCCAAATCCAAACCCC
MIC2 2 Antisense MIC2 ex 8 GAAGCTAGAGATGGCTCCAGCC
RNA preparations, RT-PCR was performed in parallel
using MIC2P-32 primers 1 and 2 under identical conditions
(Table II). MIC2P-32 transcripts are expressed ubiquitously
in human cells but are highly abundant in ETs (Kovar et al.,
1990).
In RT-PCR experiments. strict precautions were taken to
avoid cross-contamination or product carry-over that would
result in false positives. Pre- and post-amplification steps
were separated from each other. Negative controls were
included at every step of sample preparation, RNA extrac-
tion. reverse transcription and PCR. First-round PCR in-
cluded 35 cycles of denaturation at 94°C for 30 s, annealing
at 65°C for I min and elongation at 72°C for I min. PCR was
preceded by a Omin incubation at 94'C. Nested PCR was
performed with 30 cycles under the same conditions as first-
round PCR. Since primers ERG 3 and ERG 4 matched the
corresponding region of FLI-I at 18 out of 20 and at 16 out
of 18 nucleotides. respectively, the annealing temperature was
increased to 68°C for more stringent conditions. Amplified
products were analysed on 1.5% agarose gels.
DNA sequence analhsis
Sequencing was performed by the dideoxy chain-termination
method modified for fluorescent-based DNA sequencing
using an Applied Biosystems 373 DNA sequencer.
Direct sequencing of double-stranded PCR products was
carried out using the Femtomole-Sequencing System (finol,
Promega). Reaction products were analysed in 8% polyacryl-
amide gels.
HI- bridisation analysis
PCR products were routinely hybridised to EWS-. FLI-1- or
ERG-specific probes either in gel or on filters.
For in-gel hybridisation PCR products were electro-
phoresed through a 2% agarose gel which was dried for I h
at room temperature followed by 3 h at 60°C. Dried gels
were swollen in water and incubated successively in 0.5 M
sodium hydroxide, 0.15 M sodium chloride, and in 0.5 M Tris
pH 8.0. 0.15 M sodium chloride, for 30 min, each. Gels were
equilibrated in 6 x SSC (I x SSC = 0.15 M sodium chloride,
0.15 M sodium citrate, pH 7.0) for 15 min and hybridised to
radiolabelled FLI-I-specific oligonucleotide 11.6 (Table II)
for 2-3h at 60°C in 5xSSPE (I xSSPE=0.15M sodium
chloride, 0.010 M sodium hydrogen phosphate, 0.001 M
EDTA), 5 x Denhardt's solution (I x Denhardt = 0.2 g 1I
Ficoll, polyvinylpyrrolidone and bovine serum albumin) and
0.1% SDS followed by 2-3 washes with 6 x SSC.
For filter hybnrdisations gels were blotted onto a nylon
membrane (Hybond/Amersham), which was subsequently
prehybridised and hybridised to EWS-. FLI-1- or ERG-
specific probes according to standard procedures (Maniatis et
al., 1982). Hybridised gels and filters were exposed to Kodak
XAR-5 film for autoradiography.
Results
Reverse-transcribed RNA from tumour-derived material,
either cell line or primary tumour tissue, was analysed by
a
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F'ugwe 1 Representative nested RT-PCR analysis of seven
tumours selected from Table I demonstrating various EWS
fusion types. a, Ethidium bromide-stained gel. Left lane: size
markers (100 bp ladder). Corresponding patients' numbers are
indicated on top of the figure. KI, control amplification of a
reverse transcription reaction lacking RNA; K2. negative water
control. b, Hybridisation analysis of the gel shown in a using a
FLI-I cDNA probe. PCR products obtained from patients 21
and 22 which did not hybnrdise to the FLI-i probe were shown
by direct sequencing to result from EWS,ERG fusions.
PCR using primers 22.3 and 11.3 or ERG 3 respectively. The
specificity of the amplification reactions was confirmed by
nested PCR with primers 22.4 and 11.4 or ERG 4. PCR
products were routinely hybridised to EWS-, FLI-1- or ERG-
specific probes (Figure 1). Amplification products with sizes
other than those expected for the well-defined type I and type
II EWS/FLI-1 RNA as well as EWSI'ERG products were
subjected to direct sequence analysis.
EWS chimaeric RNA was detected in 28 of 30 ETs. The
processed transcripts displayed fusion of EWS exon 7 to
FLI-I exon 6 (19/28) or 5 (4/28). In this study. therefore, the
two most common EWSIFLI-I variants, type I and type II.
were detected in 68% and 14% respectively. One tumour
expressed a chimaeric transcript combining EWS exon 7 with
FLI-I exon 7. which has not been observed before. OneEWS CHIMAERIC TRANSCRIPTS AND CLINICAL DATA 911
tumour displayed a fusion of EWS exon 10 to FLI-I exon 5.
RT-PCR analysis of a cell line established from a metastasis
from patient 2 resulted in multiple amplification products. In
order to discriminate between specific and non-specific bands
all fragments were excised from the gel, reamplified using
primers 11.4 and 22.4 and subjected to direct sequence
analysis (Figure 2). The most prominent product obtained
corresponded to EWS FLI-I exon fusion 9/4. which is in
concordance with the observation of a single DNA break-
4 9W4 EWS4FLIi axon
comWb 1n
4 714
47J1
4718
4 7W9
EISex 9 FUI ex 4
TTCAATAAGCCTGGTG ACCCCACACTGTGGACA
EWSex 7 FIJI ex 4
AGCTACGGGCAGCAGA IACCCCACACTGTGGACA
EWSex7 R ex ox 6
AGCTACGGGCAGCAGA [ACCCTTCTTATGACTCA
EWSex
7 FUI1 x8
AGCTACGGGCAGCAGA ATCCGTATCAGATCCTG
EWSex7 __F1ex9
AGCTACGGGCAGCAG GAAGCGGGCAGATCCAG
Fue 2 a. Nested RT-PCR analysis of a cell line derived from
a metastasis from patient no. 2 (right lane). Arrows point to
amplification products that turned out to be derived from EUS
FLI-I chimaeric RNAs after nucleotide sequencing. EWSIFLI-I
exon combinations are indicated. All other bands resulted from
amplification of either non-specific sequences, as is often observed
in nested PCR. or and heteroduplex DNA formed between the
specific alternative products. Left lane, size marker b, Results
from sequence analysis of excised PCR products resulting from
alternative splicing.
point in EWS intron 9 (0. Delattre, personal communica-
tion). Other specific bands could be assigned to EWS/FLI-1
exon combinations 7/4, 7/6, 7/8 and 7/9, the smallest product
ever observed (Figure 2a). Since these results were obtained
repeatedly using independent RNA preparations, we do not
think that these accessory products resulted from cross-
contamination or product carry-over but rather from alterna-
tive splicing of the exon 9/4 fusion product. Two patients
(nos. 21 and 22; 7%) showed fusions of EWS exon 7 and
ERG exon 6. Therefore, a total of 93% of all tumour-derived
samples were positive by RT-PCR either for EWS/FLI-I or
EWS/ERG rearrangements.
In contrast, routine cytogenetics revealed chromosome 22
rearrangements in only 18 out of 27 tumours (67%), partly
because of failure to obtain mitotic figures (5/9) and partly
because of insufficient tumour-derived material (4/9). Fifteen
tumours revealed a t(l1;22Xq24;ql2) and one tumour a
del22q. In all of these cases an EWS/FLI-I fusion was
demonstrated by RT-PCR. In one tumour (patient 10) dis-
playing a t(2;22X4p25;ql2), no fusion transcript could be
detected although control amplifications of MIC2P-132
confirmed satisfactory quality of the RNA samples. This
tumour was a typical MIC2P3'32-positive chest wall tumour
evolving from the right ninth rib (Askin tumour) with pleural
effusion and metastases to the lungs and to the liver. In
contrast, another patient (no.21) with t(2;22flq35;ql2) ex-
pressed an EWS/ERG chimaeric RNA.
One patient (no. 5), who repeatedly failed to demonstrate
the presence of chimaeric tumour transcripts in RT-PCR
using either FLI-I or ERG-specific primers, had a tumour
from the right femur reaching to the gluteal region with bone
marrow involvement as investigated by light microscopy. The
tumour stained positive for the MIC2P34-32 antigen but was
negative for desmine and several neuroendocrine markers
(i.e. neuron-specific enolase, S1OO, ganglioside GD2, chromo-
granin). The tumour cell morphology in light microscopy was
compatible with a diagnosis of atypical Ewing's sarcoma.
The tumour karyotype was 48,XY,del(l)(p34),+ 6, + 12 with
cytogenetically normal pairs of chromosome 22, 21 and 11.
In addition, Northern blot analysis did not reveal aberrant
EWS transcripts or expression of rearranged FLI-1 RNA.
Finally. RNA extracted from all tumours with a diagnosis
other than ET (i.e. three rhabdomyosarcomas, one lym-
phoma, one neuroblastoma. one osteosarcoma and one
malignant melanoma) did not reveal any EWS chimaeric
transcript in RT-PCR.
A comparison of the distribution of primary tumour sites
with the different exon combinations revealed the following
(Table III). The relative frequency of the most common
EWSIFLI-I exon combination 7/6 - type I - (19 tumours)
was higher in tumours of the extremities (six legs, three arms)
than in central axis tumours (four chest wall, three pelvis) or
in tumours in other locations (three cases). In contrast EWS
exon 7/FLI-1 exon 5 transcripts - type II - (four tumours)
were present in tumours of the chest wall and the pelvis (two
cases each) only. Studies of the extent of disease showed that
78% (14/18) of patients with localised disease expressed type
I RNA. In contrast, type II transcripts predominated in
patients with disseminated disease at diagnosis (three cases)
as compared with localised tumours (one case). This patient
(no. 7) with a thoracopulmonary ET achieved a partial remis-
sion after two courses of chemotherapy, but shortly there-
after showed a tumour progression with lung and bone
metastases. This tumour displayed a p53 mutation, which is
very rare in patients with ET (Kovar et al., 1993), and this
may have been responsible for the aggressive tumour
growth.
In this study. EWS chimaeric transcripts were also de-
tected in two patients with extraosseous ET (nos. 22 and 23).
One tumour, evolving from the chest wall with secondary
infiltration of the scapula, showed a fusion of EWS and ERG
(no. 22). In the other case (patient 23), ET developed as a
secondary malignancy from the iliopsoas muscle after acute
lymphoblastic leukaemia and expressed a chimaeric transcript
with EWS exon 7 fused to FLI-I exon 7.912 A. ZOUBEK et al.
Table m Different exon combinations, tumour locahsation and extent of disea
Chest wall Pelvis Upper extremities Lower extremities Others Local disease Metastases
EWS ex 7/FLI-1 ex 6 4 3 3 6 3 14 5
EWS ex 7/FLI-1 ex 5 2 2 0 0 0 1 3
Otbers 1 0 0 1 1 2 1
EWS/ERG 1 0 1 0 0 1 1
Fusion transcripts and clinical outcome
Response data to chemotherapy were available for all
patients positive for EWS rearrangements. The clinical out-
come could not be evaluated in two patients because they
were lost for follow-up. Ten patients showed no evidence of
disease after a median follow-up of 21 months. Six of these
ten patients had tumours expressing EWS exon 7/FLI-I exon
6. Eight patients died as a result of disease progression. In
this subset of patients, no preference for any exon combina-
tion has been observed. Two patients in complete remission
died because of septic complications after allogeneic bone
marrow transplantation. Furthermore, six patients are still on
therapy and so far were not analysed for disease survival. In
view of the relatively short follow-up in most patients, these
results have to be considered preliminary.
Owing to the lack of differentiation, cytologically distin-
guishing ETs from other small round-cell tumours of
childhood and adolescence is often difficult. Among immuno-
logial markers only MIC2P32 is consistently highly ex-
pressed on EU cells, but it is not limited to this group of
malignancies. Because of the high inidence of chromosome
22ql2 aberrations, cytogenetic demonstration of these rear-
rangements should be pivotal to the unambiguous dignosis
of ET. However, routine cytogenetic analysis is often
hampered by non-growth of tumour cells in vitro. Moreover,
complex rearrangements with and without involvement of
chromosome 11 have been identified at the chromosomal
level in approximately 9% of cytogenetically analysable EU
cases (Turc-Carel et al., 1988). This observation might be
partially explained by the orientations of the genes involved
in the translocations: EWS and FLI-I are orientated from
the centromere to the telomere, whereas ERG is orientated
from the telomere to the centromere (Crete et al., 1993).
Presumably, in-frame fusion of EWS and ERG can only be
accomplished by either interstitial or complex translocations
involving other chromosomes. This hypothesis might explain
the lack of cytogenetic evidence for chromosome 21 re-
arrangements in EUs and the 17% translocation negatives
observed in earlier studies (Turc-Carel et al., 1988). In our
cohort patients 21 and 22 expressing EWS/ERG fit into this
category. The molcular demonstration of chimaeric EWS
RNA expression by RT-PCR as exemplified in this study
appears to be more reliable than clasical cytogenetics for ET
diaposis. Chimaerc EWS transcripts were ientf in 93%
of all cases investigated. By contrast, routine cytogenetics
displayed a chromosome 22 rearrangement in only 67% of
all tumours analysed. Only in 2 out of 30 tumours (7%)
could no EWS chimaeric transcript be revealed by RT-PCR
and Northern blotting (data not shown). In one of these
cases an EWS rearrangement was demonstrated by molecular
cytogenetics, suggesting the involvement of another so far
unidentified ETS-related gene (data not shown). The other
tumour (patient no. 5) was negative for any chromosome
22q12 rearrangement. Because of the clinical and histo-
pathological appearance this tumour was classified as
atypical Ewing's sarcoma'. However, this term is poorly
defined. Tumours assgned to this group should therefore be
reclassified on the basis ofEWS/FM-I or EWS/ERG expres-
sion. Thus, it cannot be excluded that this patient suffered
from some neoplasm other than ET. The data presented in
this report confirm the high degree of variability of EWS
chimaeric transcripts and resultant PCR products in ETs
reported earlier.
In this study, the percentage of tumours expressing either
type I or type H transcripts was 82% (23/28), which is similar
to the proportion (38/47) recently observed by Zucman et al.
(1993). The data colleted in our study from a relatively
smal number of cases suggest that the EWS/FLI-1 exon
combination 7/6 predominates in fusion transcripts of
localised tumours of the extremities, whereas the combina-
tion EWS exon 7/FLI-1 exon 5 was more frequent in meta-
static disease and tumours of the central axis. However, the
sigifi of these findings has to be carefully evaluated in
much larger cohorts of patients. Moreover, we could demon-
strate the presence of a t(11;22Xq24;ql2) and a
t(21;22Xq24;q12) in two cases of malignancies of soft tissues
at the molecular level, thus confirming the diagnosis ofextra-
osseous ET. One of these tumours, which occurred as a
second malignancy after treatment of acute lymphoblastic
leukaemia, expressed an EWS/FLI-1 exon 7/7 fusion tran-
script which has not been reported before and therefore
appears to be rare. In another unusual case with a single
defined gene rearrangement at the DNA level (data not
shown), a large EWS/FLI-1 transcript including EWS exons
1-9 as well as FLI-1 exons 4-9 was coexpressed with a
number of deduced splicing variants, all lacking EWS exons
8 and 9 and fused to FLI-I exons 4, 6, 8 or 9. In the protein
encoded by the smallest product (EWS/FLI-1 exons 7/9) the
EWS regulatory region is directly joined to the FLI-I DNA-
binding domain. This product has been predicted to occur as
a paralkl to the llt EWS/ERG fusion observed by
Zucman et al. (1993). The coexistence of alternative splicing
variants seems to be common in cells carrying chromosomal
translocations and has been demonstrated to occur in BCR/
ABL-, PML/RAR- and PBXI/E2A-positive leukaemias
(Shtivehman et al., 1986; Solomons et al., 1991; Izraeli et al.,
1992). The possible presence of multiple differentially pro-
cesed fusion transcripts in one tumour makes the applica-
tion of additional methods for specification mandatory. We
performed nested PCR as well as hybridisation to FLI-1- and
ERG-specific probes and sequence analysis in order to distin-
guish specific amplification products from non-specific ones.
Moreover, these very sensitive methods will be of particular
help in the analysis of minimal metastatic and residual
disease. The protocol applied in this report allowed detection
of one tumour cell in 10' nucleated cells by nested PCR in
multiple mixing experiments (C. Pfleiderer et al., manuscript
in preparation).
In conclusion, we think that comparison of molecular and
clinical data as initiated in this report should be extended to
much larger cohorts ofET patients since the results presented
do not exclude a biological influence of the variable hinge
region of EWS chimaeric oncoproteins on the clinical course
of the disease in EU.
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